Biosimilars in Oncology: Trastuzumab is taking off

Biosimilar launches of antineoplastic monoclonal antibodies represent a milestone in oncological care but also a new chapter in the application of biosimilars; introducing more prescribers, payers and stakeholders to the biological copies. Rituximab biosimilars came to the European market in 2017, while trastuzumab biosimilars have been keenly awaited since, and were first launched in the … More Biosimilars in Oncology: Trastuzumab is taking off

Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry?

Legal questions around the “Mischpreis” pricing approach are still hanging over sickness funds and manufacturers in Germany. The current price setting methodology as part of AMNOG negotiations take average weighted prices and considers the value and price potential across all indications and patient subgroups (‘mixed-price’). This methodology has been noted to be potentially at odds … More Pricing policy: Germany – a court ruling as soon as June could set a new tone for AMNOG pricing… but is access becoming a more complex moving target for industry?